Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Heron Therapeutics (HRTX) over the last 13 years, with Q3 2025 value amounting to $170.3 million.

  • Heron Therapeutics' Shares Outstanding (Weighted Average) rose 1146.24% to $170.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $170.3 million, marking a year-over-year increase of 1146.24%. This contributed to the annual value of $152.4 million for FY2024, which is 1036.23% up from last year.
  • Per Heron Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $170.3 million for Q3 2025, which was up 1146.24% from $152.4 million recorded in Q4 2024.
  • Heron Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $170.3 million for Q3 2025, and its period low was $98471.0 during Q4 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $118.7 million, with a median of $119.2 million in 2023.
  • Per our database at Business Quant, Heron Therapeutics' Shares Outstanding (Weighted Average) plummeted by 9989.15% in 2021 and then skyrocketed by 11046656.27% in 2022.
  • Quarter analysis of 5 years shows Heron Therapeutics' Shares Outstanding (Weighted Average) stood at $98471.0 in 2021, then soared by 110466.56% to $108.9 million in 2022, then increased by 26.87% to $138.1 million in 2023, then increased by 10.36% to $152.4 million in 2024, then increased by 11.74% to $170.3 million in 2025.
  • Its last three reported values are $170.3 million in Q3 2025, $152.4 million for Q4 2024, and $152.8 million during Q3 2024.